General Information:

Id: 10,053
Diseases: Major depressive disorder - [OMIM]
Neurological
Homo sapiens
234 patients with late-life MDD
article
Reference: Seripa D et al.(2015) Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life J. Psychopharmacol. (Oxford) 29: 623-633 [PMID: 25827644]

Interaction Information:

Comment 234 patients with late-life MDD were treated with escitalopram, sertraline, paroxetine or citalopram for 6 months. The SLC6A4 polymorphisms rs4795541-S allele (5-HTTLPR), rs140701 and rs3813034 genotypes spanning the SLC6A4 locus were investigated. 30% of the late-life MDD patients were non-responders to SSRI treatment. A significant over-representation of the rs4795541-S allele in the responder patients was observed.
Formal Description
Interaction-ID: 104900

SNP

SLC6A4 rs4795541 (short form)

decreases_activity of

disease

Major depressive disorder

in MDD patients; via responding to SSRI treatment
Comment The (5-HTTLPR) rs4795541-S allele followed a dominant model of inheritance in determining the responder phenotype and showed that such an association was evident for each rs4795541-S-allele increase.
Formal Description
Interaction-ID: 104901

SNP

SLC6A4 rs4795541 (short form)

cooccurs with

process

dominant inheritance

in MDD patients; the SLC6A4 rs4795541 (S allele) followed a dominant model of inheritance
Comment 234 patients with late-life MDD were treated with escitalopram, sertraline, paroxetine or citalopram for 6 months. The SLC6A4 polymorphisms rs4795541-S allele (5-HTTLPR), rs140701 and rs3813034 genotypes spanning the SLC6A4 locus were investigated. 30% of the late-life MDD patients were non-responders to SSRI treatment. A significant over-representation of the rs4795541-S allele in the responder patients was observed.
Formal Description
Interaction-ID: 104902

SNP

SLC6A4 rs4795541 (short form)

increases_activity of

phenotype

being responder to SSRI

in MDD patients
Comment 234 patients with late-life MDD were treated with escitalopram, sertraline, paroxetine or citalopram for 6 months. The SLC6A4 polymorphisms rs4795541-S allele (5-HTTLPR), rs140701 and rs3813034 genotypes spanning the SLC6A4 locus were investigated. 30% of the late-life MDD patients were non-responders to SSRI treatment. A significant over-representation of the rs4795541-S allele in the responder patients was observed.
Formal Description
Interaction-ID: 104903

drug/chemical compound

Escitalopram

decreases_activity of

gene/protein

SLC6A4

in MDD patients; depending on allele of SLC6A4
Drugbank entries Show/Hide entries for Escitalopram or SLC6A4
Comment 234 patients with late-life MDD were treated with escitalopram, sertraline, paroxetine or citalopram for 6 months. The SLC6A4 polymorphisms rs4795541-S allele (5-HTTLPR), rs140701 and rs3813034 genotypes spanning the SLC6A4 locus were investigated. 30% of the late-life MDD patients were non-responders to SSRI treatment. A significant over-representation of the rs4795541-S allele in the responder patients was observed.
Formal Description
Interaction-ID: 104904

drug/chemical compound

Citalopram

decreases_activity of

gene/protein

SLC6A4

in MDD patients; depending on allele of SLC6A4; a significant over-representation of the SLC6A4 rs4795541(S allele) in the responder patients was observed
Drugbank entries Show/Hide entries for Citalopram or SLC6A4
Comment 234 patients with late-life MDD were treated with escitalopram, sertraline, paroxetine or citalopram for 6 months. The SLC6A4 polymorphisms rs4795541-S allele (5-HTTLPR), rs140701 and rs3813034 genotypes spanning the SLC6A4 locus were investigated. 30% of the late-life MDD patients were non-responders to SSRI treatment. A significant over-representation of the rs4795541-S allele in the responder patients was observed.
Formal Description
Interaction-ID: 104905

drug/chemical compound

Sertraline

decreases_activity of

gene/protein

SLC6A4

in MDD patients; depending on allele of SLC6A4
Drugbank entries Show/Hide entries for Sertraline or SLC6A4
Comment 234 patients with late-life MDD were treated with escitalopram, sertraline, paroxetine or citalopram for 6 months. The SLC6A4 polymorphisms rs4795541-S allele (5-HTTLPR), rs140701 and rs3813034 genotypes spanning the SLC6A4 locus were investigated. 30% of the late-life MDD patients were non-responders to SSRI treatment. A significant over-representation of the rs4795541-S allele in the responder patients was observed.
Formal Description
Interaction-ID: 104906

drug/chemical compound

Paroxetine

decreases_activity of

gene/protein

SLC6A4

in MDD patients; depending on allele of SLC6A4
Drugbank entries Show/Hide entries for Paroxetine or SLC6A4
Comment 234 patients with late-life MDD were treated with escitalopram, sertraline, paroxetine or citalopram for 6 months. The SLC6A4 polymorphisms rs4795541-S allele (5-HTTLPR), rs140701 and rs3813034 genotypes spanning the SLC6A4 locus were investigated. 30% of the late-life MDD patients were non-responders to SSRI treatment. A significant over-representation of the rs4795541-S allele in the responder patients was observed.
Formal Description
Interaction-ID: 105158

SNP

SLC6A4 rs4795541 (short form)

increases_activity of

drug/chemical compound

Citalopram

in MDD patients
Drugbank entries Show/Hide entries for
Comment 234 patients with late-life MDD were treated with escitalopram, sertraline, paroxetine or citalopram for 6 months. The SLC6A4 polymorphisms rs4795541-S allele (5-HTTLPR), rs140701 and rs3813034 genotypes spanning the SLC6A4 locus were investigated. 30% of the late-life MDD patients were non-responders to SSRI treatment. A significant over-representation of the rs4795541-S allele in the responder patients was observed.
Formal Description
Interaction-ID: 105159

drug/chemical compound

Citalopram

decreases_activity of

disease

Major depressive disorder

in MDD patients; a significant over-representation of the SLC6A4 rs4795541-S allele in the responder patients was observed.
Drugbank entries Show/Hide entries for Citalopram
Comment 234 patients with late-life MDD were treated with escitalopram, sertraline, paroxetine or citalopram for 6 months. The SLC6A4 polymorphisms rs4795541-S allele (5-HTTLPR), rs140701 and rs3813034 genotypes spanning the SLC6A4 locus were investigated. 30% of the late-life MDD patients were non-responders to SSRI treatment. A significant over-representation of the rs4795541-S allele in the responder patients was observed.
Formal Description
Interaction-ID: 105209

SNP

SLC6A4 rs4795541 (short form)

affects_expression of

gene/protein

SLC6A4

in MDD patients
Drugbank entries Show/Hide entries for SLC6A4
Comment The biological hypothesis underlying our results is that the S allele is associated with reduced serotonin transporter expression; and thus, to a reduced density of serotonin transporters on the postsynaptic neuron and to a reduced reuptake of serotonin. This increases the time of permanence of serotonin in the synaptic cleft, as compared with the normal L allele. Accordingly, an S-carrier better respond to a drug treatment inhibiting the reuptake of serotonin, as compared with an L-carrier.
Formal Description
Interaction-ID: 105694

SNP

SLC6A4 rs4795541 (short form)

decreases_expression of

gene/protein

SLC6A4

in MDD patients; reducing the density of serotonin transporters on the postsynaptic neuron, leading to a reduced reuptake of serotonin
Drugbank entries Show/Hide entries for SLC6A4